CJC-1295 (no DAC)
Active Substance: CJC-1295
Description
What is CJC-1295 (no DAC)?
CJC-1295 (no DAC) is a synthetic peptide that functions as a Growth Hormone-Releasing Hormone (GHRH) analog. It is a modified version of the naturally occurring GHRH, specifically the first 29 amino acids of the GHRH peptide. The key difference between CJC-1295 (no DAC) and its counterpart, CJC-1295 with DAC, is the absence of a "Drug Affinity Complex" (DAC).
The "no DAC" version is also known by another name: Modified GRF (1-29) or Mod GRF. The absence of the DAC component means that the peptide has a very short half-life, which is designed to mimic the body's natural pulsatile release of growth hormone.
Benefits and Side Effects
Benefits CJC-1295 (no DAC) is often studied for its potential to stimulate the release of growth hormone (GH) and Insulin-like Growth Factor 1 (IGF-1) from the pituitary gland. These hormonal changes are associated with several potential benefits, including:
-
Muscle Growth and Repair: Increased GH and IGF-1 levels can promote muscle hypertrophy and aid in recovery from exercise.
-
Fat Loss: GH plays a crucial role in fat metabolism by increasing lipolysis (fat breakdown).
-
Improved Body Composition: By increasing muscle mass and reducing body fat, it can lead to a more toned physique.
-
Enhanced Recovery: It may accelerate the body's ability to repair from injuries and strenuous activity.
-
Anti-aging effects: Some users report improved skin elasticity, vitality, and overall well-being.
-
Improved Sleep Quality: GH is involved in regulating sleep cycles, and some users experience deeper, more restful sleep.
-
Increased Bone Density: GH is essential for maintaining and improving bone health.
Side Effects Common side effects associated with elevated GH levels, and thus with CJC-1295 (no DAC) use, can include:
-
Injection site reactions: Pain, redness, or swelling at the injection site.
-
Flushing of the face: A temporary redness or warmth.
-
Headaches: May occur due to elevated GH levels, particularly at higher doses.
-
Dizziness or Nausea: Less common, but reported by some users.
-
Water retention: Mild fluid retention can occur.
-
Carpal Tunnel Syndrome: A tingling or numbness in the hands, which can be a sign of excessive GH levels.
-
Joint or muscle pain: This can be a result of increased tissue regeneration.
Pros and Cons
Pros
-
Mimics natural GH release: The short half-life of Mod GRF (1-29) allows for dosing that more closely resembles the body's natural, pulsatile release of GH. This is often preferred by those who want to avoid the more sustained GH elevation seen with the DAC version.
-
Stacking Potential: It is often used in combination with a Growth Hormone Releasing Peptide (GHRP), such as Ipamorelin, to create a more powerful synergistic effect on GH release.
-
Dosage Control: The short half-life allows for more frequent dosing and a finer ability to titrate the dose to individual needs, potentially mitigating the risk of adverse effects.
-
Lower risk of side effects: The pulsatile release of GH may reduce the likelihood of side effects like insulin resistance or carpal tunnel, which are sometimes associated with constantly elevated GH levels.
Cons
-
Frequent Injections: The short half-life (around 30 minutes) means that to maintain elevated GH levels, multiple injections per day (often 2-3 times) are required, which can be inconvenient.
-
Requires stacking: To maximize its effects, it is almost always "stacked" with another peptide like Ipamorelin, which adds to the cost and complexity of the regimen.
-
Not a "steroid-like" effect: The effects are often subtle and gradual, not providing the dramatic, rapid changes seen with anabolic steroids.
Dosage and Frequency
There is no universally agreed-upon "official" dosage for CJC-1295 (no DAC) as it is not an FDA-approved drug for human use. However, based on anecdotal reports and research protocols, a typical dosage is often cited as:
-
Dosage: 100 micrograms (mcg) per injection.
-
Frequency: 1-3 times per day.
For maximum effect, it is typically administered on an empty stomach, either in the morning, pre-workout, or before bed to align with the body's natural GH release cycles.
Half-Life and Detection Time
-
Half-Life: The half-life of CJC-1295 (no DAC) is very short, approximately 30 minutes.
-
Detection Time: Due to its rapid metabolism, CJC-1295 (no DAC) has a short detection window. It may be detectable in drug tests for 1-2 days after administration, though this can vary depending on the dose, frequency of use, and the sensitivity of the testing method.
Sterogenic, Progestogenic, Prolactin, and Anabolic-Androgenic Effects
-
Sterogenic, Progestogenic, Prolactin Effects: CJC-1295 (no DAC) is a Growth Hormone-Releasing Hormone (GHRH) analog. Its mechanism of action is to stimulate the release of growth hormone from the pituitary gland. It does not directly bind to or affect steroid, progesterone, or prolactin receptors. Unlike some anabolic steroids or other compounds, it is not known to have direct sterogenic, progestogenic, or prolactin-raising effects. This is a key advantage, as it avoids the associated side effects like gynecomastia or suppression of natural hormone production.
-
Anabolic-Androgenic Ratio: This ratio is a metric used to compare the anabolic (muscle-building) effects of a compound to its androgenic (masculinizing) effects. This ratio is specifically relevant to anabolic-androgenic steroids (AAS), which are derivatives of testosterone. Since CJC-1295 (no DAC) is a peptide that works by stimulating growth hormone release and is not a steroid, it does not have an anabolic-androgenic ratio.
Pharmacological Properties
Half Life
0.5 hours
Active Dose
100%
Detection
0.10 days
Concentration
5000 mcg/vial
Anabolic/Androgenic Profile
Usage Effectiveness
Activity Profile
Estrogenic
None
Progestanic
None
Water Retention
None
Aromatization
No
Benefits
Dosage Recommendations
Beginner
100-200 mcg/week
Intermediate
200-300 mcg/week
Advanced
300-500 mcg/week
Evidence-based planning resources
Dive deeper into CJC-1295 (no DAC) cycle design, stacking options, and harm-reduction checklists available inside Anabolic Planner.
- CJC-1295 (no DAC) compound database overviewCompare CJC-1295 (no DAC) with other peptide agents in the structured compound index.
- CJC-1295 (no DAC) stack and cycle templatesReview evidence-based cycle outlines, dose progressions, and PCT pairings that incorporate CJC-1295 (no DAC).
- Harm-reduction guide for CJC-1295 (no DAC)Refresh safety monitoring, lab work, and countermeasure strategies tailored for CJC-1295 (no DAC) protocols.
Peer-reviewed reference material
Validate mechanisms, contraindications, and regulatory guidance for CJC-1295 (no DAC) with trusted clinical databases.
- CJC-1295 clinical research on PubMedSearch peer-reviewed human and veterinary studies discussing efficacy, endocrine impact, and contraindications.
- CJC-1295 pharmacology via Drug Information PortalReview mechanisms, synonyms, regulatory status, and toxicology summaries from the U.S. National Library of Medicine.
Side Effects
Common
Rare
Safety Information
Liver Toxicity
None
Kidney Toxicity
Low
Cardiovascular Risk
Low
Disclaimer: This information is for educational purposes only. Always consult with a qualified healthcare professional before using any compounds.